Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00436605
Other study ID # NCI-2009-00219
Secondary ID NCI-2009-00219CD
Status Completed
Phase Phase 2
First received February 15, 2007
Last updated April 29, 2014
Start date December 2006
Est. completion date November 2010

Study information

Verified date October 2011
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well dasatinib works in treating patients with stage III melanoma that cannot be removed by surgery or stage IV melanoma. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Description:

PRIMARY OBJECTIVES:

I. Determine the objective response rate in patients with stage III unresectable or stage IV melanoma treated with dasatinib.

II. Determine the progression-free survival of patients treated with this drug.

SECONDARY OBJECTIVES:

I. To assess the expression of targets of Dasatinib prior to treatment by obtaining pre-treatment biopsies or examining paraffin-embedded tissues from previous tumor resections.

II. In selected patients (approximately 5-10) where tumor tissue is available pre-treatment and can be obtained post-treatment with Dasatinib (21 days after initiation of therapy), to determine if Dasatinib induces changes in expression of selected targets and downstream mediators, including MEK, ERK and RSK-1.

III. To assess toxicity.

OUTLINE:

Patients receive oral dasatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 39
Est. completion date November 2010
Est. primary completion date March 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed stage III unresectable or stage IV melanoma

- Measurable disease

- Must have evidence of tumor growth or new lesions within the past 6 months

- No large pleural effusions

- No known brain metastases or leptomeningeal metastases

- Previously treated brain metastases allowed provided there is no requirement for steroids AND no evidence of progression for = 8 weeks after treatment

- ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%

- Life expectancy > 3 months

- WBC = 3,000/mm³

- Absolute neutrophil count = 1,500/mm³

- Platelet count = 100,000/mm³

- Hemoglobin = 9.0 g/dL (transfusions allowed)

- Bilirubin = 1.5 mg/mL

- AST and ALT = 2.5 times upper limit of normal (ULN)

- PT/INR and PTT normal

- Creatinine = 1.5 times ULN OR creatinine clearance = 60 mL/min

- No medical condition that may affect the ability to swallow and retain dasatinib tablets, including any of the following:

- Gastrointestinal tract disease resulting in an inability to take oral medication

- Requirement for IV alimentation

- Prior surgical procedures affecting absorption

- Active peptic ulcer disease

- No clinically significant cardiovascular disease, including any of the following:

- Myocardial infarction or ventricular tachyarrhythmia within the past 6 months

- Prolonged QTc > 480 msec

- Major conduction abnormality (unless a cardiac pacemaker is present)

- No uncontrolled intercurrent illness including, but not limited to, any of the following:

- Ongoing or active infection

- History of significant congenital or acquired bleeding disorder, including any of the following:

- Von Willebrand's disease

- Antifactor VIII antibodies

- Dyspnea at rest or with minimal exertion

- Uncontrolled seizure disorder

- Psychiatric illness or social situations that would preclude study compliance

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No other active malignancy within the past 3 years except curatively treated stage I malignancies or resected skin carcinomas

- Recovered from prior therapy

- Prior adjuvant therapy for stage II or III melanoma allowed

- No prior cytotoxic therapy for metastatic melanoma

- No prior dasatinib or other inhibitors of src, bcr-abl, c-Kit, EPHA2, and PDGFRß

- No more than 2 prior immunomodulator therapies for metastatic melanoma

- At least 1 week since prior and no concurrent warfarin or other anticoagulants or medications that inhibit platelet function (including acetylsalicylic acid)

- At least 1 week since prior and no concurrent steroids or other immunosuppressive agents

- Concurrent steroids to treat induced pleural effusions allowed

- At least 3 weeks since prior immunomodulators including, but not limited to, any of the following:

- Aldesleukin

- Cancer vaccines

- T-cell-activating monoclonal antibodies

- At least 4 weeks since prior radiotherapy

- Prior palliative radiotherapy to a single site of disease allowed (tumor is not considered evaluable for response unless there is tumor progression at the site of radiation)

- More than 7 days since prior and no concurrent CYP3A4 inhibitors

- At least 7 days since prior and no concurrent agents with proarrhythmic potential

- No other concurrent investigational agents

- No other concurrent anticancer agents or therapies

- No concurrent enzyme-inducing anticonvulsant agents

- No concurrent grapefruit or grapefruit juice

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No concurrent CYP3A4 inducers

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
dasatinib


Locations

Country Name City State
United States Masonic Cancer Center, University of Minnesota Minneapolis Minnesota
United States Yale University New Haven Connecticut

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects With Objective Response(Partial Response and Complete Response) as Measured by RECIST Criteria Only those patients who have measurable disease present at baseline, have received at least one course of therapy, and have had their disease re-evaluated will be considered evaluable for response. A Simon's optimum two-stage design will be used. After every 8 weeks (or 2 courses), assessed up to 4 weeks after completion of treatment No
Primary Progression-free Survival Progression will be evaluated in this study using the new international criteria proposed by the RECIST Committee. A Simon's optimum two-stage design will be used Time from start treatment to time of progression, assessed up to 6 months No
See also
  Status Clinical Trial Phase
Completed NCT02107755 - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Phase 2
Withdrawn NCT01216787 - RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery Phase 2
Active, not recruiting NCT01026324 - Dinaciclib in Treating Patients With Stage III-IV Melanoma Phase 1/Phase 2
Completed NCT01010984 - LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma N/A
Completed NCT00553306 - Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma Phase 1/Phase 2
Completed NCT00121225 - Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Phase 2
Completed NCT00019448 - Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma Phase 2
Active, not recruiting NCT03200847 - Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma Phase 1/Phase 2
Active, not recruiting NCT03235245 - Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib Phase 2
Terminated NCT01875653 - Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma Phase 3
Completed NCT01748747 - Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery Early Phase 1
Terminated NCT01316692 - Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma Phase 2
Active, not recruiting NCT01120275 - Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma Phase 2
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1
Terminated NCT01166126 - Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV Phase 2
Terminated NCT01026051 - Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma Phase 2
Completed NCT01037790 - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Phase 2
Completed NCT00288041 - Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00074308 - Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers Phase 1/Phase 2
Completed NCT00072163 - Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma Phase 2